NCT02537418 - Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

October 16, 2015

Primary Completion Date

July 20, 2018

Study Completion Date

January 30, 2026

Conditions

Solid Malignancies

Interventions

DRUG

durvalumab

DRUG

tremelimumab

Trial Locations (7)

Tom Baker Cancer Centre, Calgary

BCCA - Vancouver Cancer Centre, Vancouver

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

Cancer Centre of Southeastern Ontario at Kingston, Kingston

Ottawa Hospital Research Institute, Ottawa

University Health Network, Toronto

CHUM - Hopital Notre-Dame, Montreal